Skip to main content

Education First

Site section 6 of 12

Receptors, ligands and signal transduction

A professional mechanism bridge for receptor vocabulary, ligand action, allosteric modulation, affinity, potency, efficacy, selectivity, signal transduction, species limits, and the line between cell signal and human outcome.

Learning progress

Progress is private to this browser.

Mechanism bridge

Learn the receptor machinery before reading any named example.

The course starts with terms and measurement. Only after the mechanism is mapped does it explain how catalog receptor-family illustrations should be read: structural and source context, not product-to-outcome evidence.

Lessons
13
Core readouts
5 levels
Claims mode
RUO only

Boundary lock

Educational receptor pharmacology and cell-signaling context only. This course does not provide medical advice, diagnostic interpretation, treatment guidance, prevention guidance, dosing guidance, administration guidance, human-use guidance, veterinary-use guidance, safety claims, efficacy claims, or evidence that any catalog item changes a biological or human outcome.

Allowed

Define receptor terms, assay readouts, source context, and inference limits.

Excluded

No medical, diagnostic, treatment, prevention, human-use, veterinary-use, or product-effect claims.

Bridge rule

Cell signaling does not equal human outcome without bridge evidence at every level.

Dose-response, the model

How a response climbs from a threshold to a ceiling as concentration rises: EC50 shifts the curve, the Hill slope changes its width, and Emax sets the ceiling; the rise from a tenth to nine tenths spans 81^(1/n) in concentration.

Modeled
1.00The model’s own maximum response, as a fraction of a full ceiling.
1.50Steepness of the climb; higher n narrows the rise.
midWhere the half-maximal point sits on the numberless concentration axis.
midScrub here or drag on the plot; the axis carries no unit and no number.

Response

50%

on the response axis, the value under the needle (climbing); 50 % of the ceiling you set

Ten-to-ninety span

18.72fold

81^(1/n) in concentration; the dashed n = 1 reference spans 81 fold

At the half-maximal point

The scrubbed concentration sits at the EC50 you set, so the model returns half of its own ceiling (50 percent here, at the scrub’s resolution). This is the inflection of the curve on the log-concentration axis, where the climb is at its steepest.

In this model, with the scrubbed concentration at the EC50 you set, the response axis reads 50 percent, which is 50 percent of the ceiling you set. EC50 and slope are parameters you set, not measured for this lot.

Method and sources

response = Emax / (1 + 10^(n (log EC50 − log C)))

What it shows: The general S-shaped relationship many chemical sequences are described by: as concentration rises the response stays near zero, then climbs, then flattens at a ceiling. The midpoint of the climb is the EC50, the half-maximal point.

How to read it: Move EC50 to shift the whole curve left or right, raise the Hill slope n to sharpen the climb (the dashed curve keeps the slope of one for reference), lower Emax to drop the ceiling, and scrub on the plot or with the control to read the model fraction at any concentration. The concentration axis carries no numbers on purpose: the shape is the point.

Assumptions: A single Hill relationship with one EC50 and one slope; no measured concentration, response, EC50 or ceiling for any lot; no variance, so no uncertainty band is drawn.

Sources: None stated: the parameters are yours to set.
A model of the general concentration-response relationship that you drive. Parameters are yours to set; not measured for any lot; not an efficacy or dosing claim. No uncertainty band is drawn: this model has no fit and no stated variance to draw one from.

A sigmoid on a numberless concentration axis rising from near zero to the ceiling you set. A caret on the axis marks the EC50 you set; a bracket above the field spans the rise from a tenth to nine tenths of the ceiling; the needle sits at the concentration you scrubbed. When the Hill slope is not one, a dashed reference curve shows the same EC50 and ceiling at a slope of one.

Check yourself

Do not jump from receptor art to outcome claims.

A learner sees a receptor-family figure and wants to infer a product effect. The course has to route them back through ligand action, concentration, cell context, and measurement readouts.

Choose the next move

Pick an answer to see why.

Course spine

Thirteen lessons, each with a measurement boundary.

Every lesson defines what the concept is, what can be measured, which units apply, what dynamics matter, what the concept cannot prove, and how to handle an ambiguous case.

  1. 01 / Boundary: mechanism is not outcome

    State the difference between receptor mechanism, measured cell signal, and organism-level outcome.

  2. 02 / Receptor and ligand vocabulary

    Define receptor, ligand, target, binding site, orthosteric site, allosteric site, and transduction.

  3. 03 / Target-family atlas

    Compare GPCRs, catalytic receptors, ion channels, nuclear receptors, pattern sensors, enzymes, and transporters.

  4. 04 / Binding interface and occupancy

    Explain binding-site fit, occupancy, association, dissociation, and why binding is not activation.

  5. 05 / Orthosteric agonism

    Distinguish full agonist, partial agonist, inverse agonist, and activator using receptor-state language.

  6. 06 / Antagonism and blockade

    Separate competitive antagonism, noncompetitive antagonism, channel block, and inverse agonism.

  7. 07 / Allosteric modulation

    Define positive, negative, and neutral allosteric modulation without treating modulation as outcome proof.

  8. 08 / Affinity, potency, and efficacy

    Explain why affinity, potency, and efficacy answer different questions.

  9. 09 / Selectivity and off-target context

    Define selectivity as comparative behavior across targets, species, and assay systems.

  10. 10 / Signal transduction cascade

    Trace receptor engagement to second messengers, kinases, phosphatases, transcription, and feedback.

  11. 11 / Desensitization and receptor trafficking

    Explain why receptor response can change over time even when ligand remains present.

  12. 12 / Measurement and inference

    Match binding, functional, pathway, cell, tissue, and organism readouts to the conclusions they can and cannot support.

  13. 13 / Species and context bridge

    Explain why species, cell background, exposure, metabolism, and organism context limit translation.

Vocabulary

Terms stay attached to readouts and units.

The course avoids loose labels. Receptor, ligand, agonist, antagonist, allosteric regulator, affinity, potency, efficacy, and selectivity each answer a different evidence question.

Receptor

A cellular macromolecule that receives a ligand or stimulus and changes state in a way that can route downstream signaling.

Measured by
binding assay, functional assay, structural assay, pathway assay.
Units
not applicable for the term, assay-specific units for receptor readouts.

Ligand

A molecule that binds a target site; ligand identity alone does not define agonism, antagonism, or outcome.

Measured by
binding assay, competition assay, functional assay.
Units
nM or microM for concentration, unitless occupancy fraction.

Orthosteric ligand

A ligand that binds the same site as the physiological agonist of the receptor.

Measured by
competition binding, functional agonist or antagonist assay.
Units
nM or microM, percent response.

Agonist

A ligand that binds a receptor and alters receptor state in a way that produces a biological response in the tested system.

Measured by
concentration-response curve, second messenger assay, current assay, reporter assay.
Units
EC50 concentration, Emax response.

Partial agonist

An agonist that cannot elicit as large a system response as a reference agonist under the same conditions, even at high occupancy.

Measured by
matched concentration-response curve.
Units
Emax percent of reference, EC50 concentration.

Antagonist

A ligand that reduces the action of another ligand, generally an agonist, in a defined system.

Measured by
agonist curve in antagonist conditions, competition assay.
Units
nM or microM, percent inhibition, fold shift.

Inverse agonist

A ligand that reduces the fraction of unoccupied receptors in an active conformation when basal activity exists.

Measured by
basal activity assay, active-state sensor.
Units
percent basal reduction, nM or microM.

Allosteric regulator

A ligand that binds a distinct site and increases or decreases another ligand’s action.

Measured by
orthosteric and allosteric ligand matrix, fold shift, response surface.
Units
fold shift, percent potentiation, percent inhibition.

Affinity

A binding tendency estimated under specified assay assumptions; it is not the same as functional efficacy.

Measured by
Kd, Ki, competition binding.
Units
nM or microM.

Potency

The concentration needed to produce a defined response in a defined assay system.

Measured by
EC50, IC50.
Units
nM or microM.

Efficacy

The ability of a bound ligand to produce response in the system being measured.

Measured by
Emax, relative maximal response, pathway output.
Units
percent response, relative assay units.

Selectivity

Preference for one target, subtype, or subunit over comparators under specified assay conditions.

Measured by
matched target panel, fold selectivity, curated activity table.
Units
unitless fold ratio, nM or microM comparator values.

Target architecture

Families determine readout logic before examples appear.

A GPCR, catalytic receptor, ion channel, nuclear receptor, and intracellular mediator network produce different first signals and different measurement requirements.

Receptor family atlas

Select a family to compare architecture, input, immediate output, timing, and the boundary that keeps family context separate from effect claims.

Receptor family

GPCR

Architecture
Seven-transmembrane receptor coupled to heterotrimeric G proteins and often beta-arrestin trafficking context.
Input
Extracellular ligand, sensory stimulus, or receptor-state stabilizer.
Immediate output
G protein GDP/GTP exchange, second messengers, kinase routes, beta-arrestin context.
Timing
Seconds to minutes for early signals; longer for trafficking and transcriptional effects.
Catalog context
Class A GPCR plate, Class B GPCR plate
Limit
A GPCR-family relationship does not prove ligand activity, potency, selectivity, or human outcome.

Quantitative pharmacology

Affinity, potency, and efficacy are not synonyms.

The general dose-response model at the top of this course separates the EC50 inflection, the Hill slope, and the ceiling, which is why potency, steepness, and maximal response move independently. The axes carry no real numbers on purpose.

Ligand actions

Agonism, antagonism, and allosteric modulation are assay claims.

Each label requires receptor site, reference condition, unit contract, readout, and boundary. The workbench keeps that evidence visible.

Ligand action workbench

Activity labels only make sense with binding site, assay readout, unit contract, and boundary attached.

Ligand action

Full agonist

Binding site
Orthosteric
Receptor-state effect
Stabilizes active receptor states enough to reach the system’s maximal response under the tested conditions.
Measured readout
Reference-normalized Emax and EC50 in a matched concentration-response assay.
Boundary
Full in one system does not mean full in every tissue, species, or assay.
Unit contract
EC50 in nM or microM, Emax in percent or relative assay units

Allosteric modulation matrix

Positive, negative, and neutral allosteric states are probe-dependent. The matrix keeps orthosteric ligand, allosteric ligand, receptor state, and readout visible at the same time.

Positive allosteric modulator

Increases affinity, efficacy, or response to an orthosteric ligand in a specified assay.

Probe dependence and receptor state must be named.

Negative allosteric modulator

Decreases affinity, efficacy, or response to an orthosteric ligand in a specified assay.

Negative modulation is not automatically noncompetitive antagonism in every system.

Neutral allosteric ligand

Binds an allosteric site without changing the orthosteric ligand response, while potentially blocking another allosteric ligand at that site.

Neutral does not mean biologically irrelevant; it means neutral for the measured orthosteric response in that assay.

Signal transduction

Reception, transduction, response, feedback.

The course treats signaling as a timed network: receptor state, G proteins, kinases, phosphatases, adapters, second messengers, transcription, desensitization, trafficking, and termination.

Signal transduction cascade

Signal transduction is the conversion of receptor-state information into intracellular biochemical events and cellular response.

Cannot prove: A pathway signal cannot prove causal relevance to a tissue or organism without additional model design. One measured node can miss parallel, compensatory, or delayed branches.

Desensitization and receptor trafficking

Desensitization, sequestration, internalization, recycling, and downregulation describe time-dependent changes in receptor availability and coupling.

Cannot prove: A single endpoint can miss adaptation, recovery, and receptor reserve. Trafficking in engineered cells may not match native tissue biology.

Measurement and inference

A measurement ladder that distinguishes direct binding evidence, receptor function, downstream pathway evidence, cell-state evidence, tissue evidence, and organism evidence.

Cannot prove: No single in vitro readout establishes human outcome. Model systems have expression, species, metabolism, exposure, and context limits.

Species and context bridge

A final integration lesson that names the evidence needed to move from a target claim to a human-outcome claim.

Cannot prove: The course cannot infer human safety or benefit from target or cell-signaling evidence. Catalog sequence documentation remains identity and quality context, not outcome evidence.

Measurement

Cell signaling does not equal human outcome.

The inference ladder names what each readout can show and what it cannot show alone. This is the course’s central mechanism bridge.

Inference ladder

Each readout moves one level higher only when bridge evidence is present. The ladder is built to stop the jump from receptor signal to human outcome.

01

Binding assay

Can show: Ligand-target interaction, competition, affinity-like estimates, or occupancy under assay assumptions.

Cannot show alone: Activation, efficacy, downstream signaling, tissue response, safety, or human outcome.

02

Functional assay

Can show: Agonism, antagonism, modulation, Emax, EC50, IC50, slope, or response amplitude in a defined model.

Cannot show alone: Universal potency, selectivity, organism effect, or clinical meaning.

03

Pathway time course

Can show: Sequence and timing of second messenger, phosphorylation, localization, or transcriptional events.

Cannot show alone: The full causal pathway, tissue relevance, or human outcome.

04

Cell-state assay

Can show: Cell morphology, viability, secretion, transcript, protein, or phenotype shifts in a model system.

Cannot show alone: Specific receptor causality or organism-level effect without bridge controls.

05

Organism study

Can show: Integrated exposure, metabolism, feedback, and model endpoint when designed and controlled for that purpose.

Cannot show alone: Direct receptor mechanism unless target engagement and pathway bridges are measured.

Catalog bridge

Receptor-family images are documentation context.

When a catalog page shows a receptor-family plate, the allowed interpretation is structural context and source orientation. It is not proof of binding, activation, tissue response, safety, or human outcome.

Mechanism, not outcome

copy gate

Replace outcome language with evidence-level language: receptor context, assay readout, model limit, and unknown bridge.

Allowed: teaches receptor vocabulary, explains mechanism categories, names evidence needed for activation claims

Database context

copy gate

State whether the evidence is nomenclature, binding, functional activity, structural context, or outcome evidence.

Allowed: curated target context, database source anchor, target-family record

Family, not effect

copy gate

Keep receptor-family structure separate from measured ligand activity and biological response.

Allowed: representative family topology, structural context, readout category

Assay-specific response

copy gate

Attach every activity label to assay system, species, reference ligand, concentration range, and readout.

Allowed: in this assay, under these conditions, relative to this reference ligand

Numeric context

copy gate

Define the parameter, unit, assay, reference, and what the parameter cannot establish.

Allowed: EC50 in concentration units, Emax in assay units, fold selectivity in matched panel

Cell signal, not outcome

copy gate

Move from signal to outcome only when target engagement, pathway, exposure, tissue, organism, and controlled outcome evidence are all named.

Allowed: cell-signaling readout, pathway node, model-system response

Species context limit

copy gate

Name species, target homolog, cell background, assay, exposure, and missing bridge evidence.

Allowed: species-specific, cell-background-specific, context-limited

Sources

Source anchors stay visible.

The course uses IUPHAR/BPS for pharmacology vocabulary and NIH/NIGMS/NCBI sources for receptor biology, transduction, and inference boundaries.

Source record

These sources support receptor vocabulary, ligand action labels, signal transduction architecture, and inference limits. They are not cited as evidence that any catalog item changes a biological outcome.

Education First course pipeline

Defiance

The method every course follows: cited sources, claims boundaries, and review before publication.

Accessed 2026-07-02 / stable

IUPHAR/BPS Guide to Pharmacology

IUPHAR/BPS

Expert-curated pharmacological target and ligand knowledgebase; used for target-family and ligand-activity source hierarchy.

Accessed 2026-07-02 / recheck-before-release

Source: IUPHAR/BPS Guide to Pharmacology

IUPHAR/BPS Guide to Pharmacology help: ligand actions

IUPHAR/BPS

Definitions for agonist, partial agonist, antagonist, inverse agonist, allosteric regulator, orthosteric ligand, selectivity, and ligand context.

Accessed 2026-07-02 / recheck-before-release

Source: IUPHAR/BPS Guide to Pharmacology help: ligand actions

IUPHAR/BPS Guide to Pharmacology in 2026

Nucleic Acids Research

Current Guide to Pharmacology database scope, target and ligand curation context, and official nomenclature role.

Accessed 2026-07-02 / recheck-before-release

Source: IUPHAR/BPS Guide to Pharmacology in 2026

Physiology, Cellular Receptors

NCBI Bookshelf

Cellular receptor overview, ligand-triggered conformational change, receptor families, and signaling outputs.

Accessed 2026-07-02 / recheck-before-release

Source: Physiology, Cellular Receptors

Cell Surface Receptors and Their Signal Transduction Pathways

NCBI Bookshelf

Textbook-level mechanism bridge from ligand binding to receptor conformational change, phosphorylation cascades, and transcriptional outputs.

Accessed 2026-07-02 / stable

Source: Cell Surface Receptors and Their Signal Transduction Pathways

Biochemistry, G Protein Coupled Receptors

NCBI Bookshelf

GPCR activation, G protein GDP/GTP exchange, second messengers, desensitization, internalization, and downregulation.

Accessed 2026-07-02 / recheck-before-release

Source: Biochemistry, G Protein Coupled Receptors

Pharmacodynamics

NCBI Bookshelf

Emax, EC50, Hill coefficient, direct versus indirect pharmacodynamic actions, and measured-parameter limits.

Accessed 2026-07-02 / recheck-before-release

Source: Pharmacodynamics

NIGMS research areas: cell surface receptors, ligands, and intracellular mediators

NIH/NIGMS

Basic-science scope for cell surface receptors, endogenous ligands, GPCRs, kinases, phosphatases, adapter proteins, lipid messengers, and compartmental signaling.

Accessed 2026-07-02 / recheck-before-release

Source: NIGMS research areas: cell surface receptors, ligands, and intracellular mediators

Editorial scope: chemical identity, experimental context, analytical methods, source quality and regulatory boundaries. Source references and stated limitations form part of the material; they should remain attached to quotations or summaries.

Biological systems path